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Background: After more than a decade of establishing and expanding access to highly active antiretroviral therapy
(HAART), empirical evidence on its impact on trends of opportunistic infections (OIs) associated with the deadly
human immunodeficiency virus (HIV) in resource poor settings is scarce. The primary objective of this study was to
assess the effect of HAART coverage on trends of five most common OIs in Uganda.
Methods: Observational data from January 2002 to December 2013 for 5972 HIV positive individuals attending the
AIDS Support Organisation (TASO) HIV/AIDS care programme in Uganda were extracted and analysed. Trends were
analysed using autoregressive moving average time series and mixed effects linear regression models adjusting for
all available potential confounders.
Results: A total of 204,871 monthly medical reports were retrieved and analysed. Majority of the participants were
female (73%) with a median age of 32 years (inter-quartile range 26–39). Overall, significant decreasing mean
annual prevalence trends were observed for Mycobacterium tuberculosis, herpes zoster, genital ulcer and oral
candidiasis (p < 0.05, X2trend). Non-significant declining mean annual prevalence trend was observed for cryptococcal
meningitis (p = 0.181, X2trend). The largest impact of HAART was observed in Oral candidiasis and TB whose average
annual prevalence reduced by 61% and 43% respectively following the introduction of HAART. Monthly series for
TB, Herpes zoster and genital ulcers differed significantly by age and clinic but only genital ulcer series differed
significantly by sex (p < 0.05, kruskal wallis). After controlling for the effects of age, sex and clinic (fixed) and monthly
clustering (random effect) in a mixed effects linear regression model, all the five OIs showed a significant monthly
change in prevalence (p < 0.001).
Conclusion: Overall, prevalence of most OIs declined especially after the introduction of HAART. However
significant variations exist in the trends of different OIs in different geographical areas in Uganda. It is therefore
important that site specific factors are properly identified to enable the development of targeted interventions.Background
Since the outbreak of HIV in 1981, an estimated 39 million
people worldwide have died and about 35 million are living
with the deadly virus with Sub-Saharan Africa suffering the
greatest brunt of the epidemic [1]. Opportunistic infections
(OIs) remain the single main cause of ill-health and death
among HIV-infected patients [2-4]. Research shows that
about 90% of HIV-related morbidity and mortality are
caused by opportunistic infections compared to 7% due to
opportunistic cancers and 3% due to other causes [5].* Correspondence: rubaihayoj@yahoo.co.uk
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unless otherwise stated.However, this may have changed since the introduction of
HAART in mid-1990s in developed countries [6-10].
HAART is known for effective suppression of systemic
HIV viral load and immune restoration thereby reducing
the frequency of opportunistic infections, deferring mor-
bidity and mortality hence improving survival among HIV
infected individuals [7,11,12].
Several developing countries are slowly scaling up access
to HAART, amidst scarcity of resources and uncertainty
for a sustained lifelong provision of treatment to an ever
increasing number of eligible HIV patients [1]. By end of
2013, about 13million HIV patients had access to HAART
globally with 9.2million from middle and low income
countries [13]. In resource poor settings, HIV positive in-
dividuals usually access care and treatment with markedtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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whose spectrum and frequencies may vary over time and
in different countries or even within the same country
[3,14]. OIs lower the quality of life of persons living with
HIV/AIDS (PLHA), increases stigma and limits one’s abil-
ity to work and are usually associated with high medical
care costs. Opportunistic infections therefore have greatly
contributed to poverty among those infected and affected
by HIV hence may be an impediment to the attainment of
the millennium development goals (MDGs) on health and
poverty eradication in resource poor settings.
Previous studies in developed countries show varied
results on the effect of HAART on opportunistic infec-
tions over time and in different geographical areas
[11,15-17]. For example a study in the USA that evalu-
ated annual trends for 13 most common AIDS-defining
opportunistic infections by examining medical records
in more than 90 hospitals and clinics in 9 US cities be-
fore HAART (1991–96) showed decreasing trends in 5
OIs (PCP, esophageal candidiasis, tuberculosis, herpes
simplex and cryptosporidiosis) and an increasing trend
in recurrent pneumonia [11]. The trends in the time of
onset, spectrum and frequency of infections was found
to be unique for different OIs and varied by level of
immune-suppression [11].
In another study in the USA, opportunistic infection
rates varied considerably among US-born, Mexican-born
and central American-born Latinos in the era of
HAART. U.S.-born Latino women were more likely than
Central American born Latino women to develop an OI
(hazard ratio = 2.9, CI: 1.3, 6.5). In a Poisson regression
analysis, U.S.-born Latino men and women combined
were at greater risk of Kaposi’s sarcoma (RR 2.9, 95%
CIs: 1.1, 7.6, p = 0.03) and yet for esophageal candidiasis,
there was no evidence of a change in rate between the
three communities [18].
Another study in the USA that reviewed the trends in
the epidemiology of opportunistic fungal infections asso-
ciated with HIV/AIDS reported an increasing trend in
the incidence of fungal infections (Aspergillus sp) attrib-
uted to increasing resistance to anti-fungal treatment
and recommended documentation of epidemiological
trends to gain more insights into the effectiveness of
treatment strategies [19]. A study in Spain that exam-
ined temporal trends in the incidence of opportunistic
infections (OIs) associated with AIDS in the period
1989–1997 showed a significant decreasing trend in
esophageal candidiasis, pulmonary and extra-pulmonary
tuberculosis, and cerebral toxoplasmosis. However an
increasing but non-significant trend of MAC incidence
over time [20]. In Brazil, trends of OIs among HIV-
infected adults (>12 years old) at a national level in the
period between 1980 and 1999 declined significantly but
not homogeneously by regions, risk groups, educationand sex [21]. In Northeast and Central-West regions,
they showed an increasing trend for TB and Toxoplas-
mosis. TB had higher incidence among those with lower
education (>8 years) while PCP and KS had higher inci-
dence among those with 8+ years of education, despite
having similar trends of decline.
Few studies have examined the effect of HAART on
trends of OIs in the African settings. One of these few
studies examined the trends in incidence rates of TB in
HIV-negative adults in South Africa before HAART and
reported an increasing trend of TB incidence (test for
trend P = 0.17) [22]. Given the scale and speed at which
HAART roll-out is taking place in sub-Saharan Africa
and in view of the policy changes in HAART access over
time [23], it is important to evaluate the impact of these
costly HIV interventions in resource poor settings.
Uganda is among African countries with the highest bur-
den of HIV/AIDS [24]. Currently there are an estimated
1.5 million people living with HIV/AIDS with about 60%
in need of HAART [13]. HAART rollout began in 2004 as
part of the Global HAART roll out strategy and the na-
tional target is to provide HAART to 80% of the popula-
tion in need by 2015 [25]. However, the impact of the
increasing coverage of HAART on trends of OIs in the
country has previously not been examined due to lack of
sufficient data. The primary objective of this study was to
evaluate the impact of HAART coverage on trends of five




Observational data for 5972 HIV positive individuals were
obtained from the AIDS support organisation (TASO)
in Uganda and analysed. The period of study was from
January 2002 to December 2013 including 2 years be-
fore and 10 years after HAART introduction in Uganda.
The OIs of interest were cryptococcosis, tuberculosis,
oral candida, herpes zoster and genital ulcer. These
were chosen on the basis of being the commonest OIs
among HIV+ individuals in Uganda and are easily diag-
nosed. The review period was categorised into three
mutually exclusive time periods that signify important
milestones in the prevention and treatment of opportunis-
tic infections associated with HIV/AIDS in Uganda. First
period (2 years) was from January 2002 to December 2003
in which HIV+ individuals had no access to HAART. Sec-
ond period (5 years) was from January 2004 to December
2008 denoted as “Early HAART” in which HAART access
was limited to severely ill HIV+ individuals (CD4 count
<200 cells/μl of blood) as per World Health organisation
2006 HAARTaccess guidelines [26]. Third period (5 years)
was from January 2009 to December 2013 denoted as
“Late HAART” in which a lot of experience in HAART
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changed to include all HIV+ individuals with CD4 cell
count ≤350 cells/ μl of blood as per World Health organ-
isation 2010 HAART access guidelines [27].
Settings
The study was conducted in TASO, one of the oldest
and largest HIV/AIDS care and treatment non-
governmental organisation (NGO) in Uganda and sub-
Saharan Africa [28]. TASO has 11 HIV clinics nationally
recognised as centres of excellence with excellent labora-
tory practice and management supported by Centre for
Disease Prevention and Control (CDC) [29]. With close
to 3 decades of experience in HIV/AIDS care and treat-
ment, TASO provided a good opportunity for assessing
OI trends in real life programmatic settings in which
HAART roll out is taking place in sub-Saharan Africa
[30]. TASO ART programme started as part of the Na-
tional ART roll-out programme in public health facilities
in 2004. Being one of the largest ART providers in the
country, TASO got support from different funders sup-
porting ART programmes in sub-saharan Africa including
the President’s Emergency Plan for AIDS Relief (PEPFAR)
and the Global Fund to Fight AIDS, Tuberculosis and
Malaria. Initially, access to HAART was based on the
Ugandan ministry of Health and the World Health Or-
ganisation (WHO) 2006 guide lines i.e. WHO stage 3
or 4 illness or a CD4 cell count < 200 cells/μl for adults
and adolescents and WHO stage III, advanced stage II
or stage I with CD4 cell percentage less than 20% for
those more than 18 months of age [26]. However, after
2010 access to HAART was expanded to include HIV
patients with CD4 cell count ≤ 350 or WHO clinical
stage3 or 4 irrespective of CD4 cell count as was recom-
mended by Ugandan Ministry of Health and WHO
[27,31]. Clients who are not eligible for HAART are usu-
ally offered cotrimoxazole or dapson prophylaxis. By end
of 2013, a total of 91,218 were actively in care of which
58,051 clients (64%) were on HAART and 87,903 (96.4%)
were on cotrimoxazole/dapson prophylaxis throughout
the 11 HIV clinics across Uganda [29]. All services are free
of charge including anti-retroviral drugs (ARVs) for those
who are eligible [30]. Though TASO data system was not
set up to answer any particular research question, but with
assistance from Centre for Prevention and Disease Control
(CDC) and other partners, TASO has been able to put up
a large and up to date HIV/AIDS data base that can be
used to inform and guide national policy on HIV/AIDS in
Uganda [28].
Sampling and sample size
Three TASO HIV clinics were purposively selected basing
on volume and quality of data necessary for analyzing
trends of most common OIs as well as less common OIsand geographical representation. The HIV clinics selected
were TASO Mulago HIV clinic in central Uganda, TASO
Mbarara HIV clinic in south-western Uganda and Tororo
HIV clinic in Eastern Uganda. All clients irrespective of
age who were in care at the three selected HIV clinics by
1st January 2002 were included in the study.
Data collection
Data on OIs were obtained from the TASO electronic
data bases at the three HIV clinics and TASO headquar-
ters in Kampala. The data were collected by TASO med-
ical staff following an established protocol for all TASO
HIV clinics. In brief, each client was expected to attend
the clinic at least once a month. At each clinic visit, data
per client was collected on a standardized medical form
detailing the client’s demographic information, clinical
condition, medical history, OI diagnosis, ART use and
level of adherence, prophylaxis use, any other treatment
given and side effects/toxicities if any. Diagnosis of OIs
was based on the Ugandan ministry of health guidelines:
Sputum tuberculin positive test or a chest radiography
and/or GeneXpert positive test for TB; A CRAG positive
test for Cryptococal meningitis; persistent creamy white
curd-like plagues or red patches on the tongue, palate or
lining of the mouth for oral candida; progressive and
painful genital ulceration for genital ulcers and painful
vesicular skin blisters with a dermatomal distribution for
herpes zoster. All medical data were compiled and en-
tered into the TASO electronic data base by TASO data
administrator using EPIINFO vs3 in Access format.
Monthly medical data for each participant covering the
period January 2002 to December 2003 were extracted
by the data administrator, delinked from overt identifiers
and then handed over for analysis.
Data management and analysis
Data management and analysis was done using STATA
12 (Stata Corp, Collage station, Texas, USA). Data were
exported from epiinfo/access format to STATA 12 and
cleaned. Data cleaning involved data reduction, deleting
duplicates and missing data checks. To analyse trends,
data on each OI was re-assembled and summarised by
year and month. Then monthly and average annual
prevalence for each OI were plotted. Monthly prevalence
was calculated from the total number of clients recorded
with an event in a month divided by the total number
that attended the clinic in that month. Annual prevalence
per OI was calculated from the mean of the monthly
prevalences in a year.
To establish whether there is a trend, prevalence of
each OI by month and calendar year were first tabulated
and then a monthly time plot for prevalence of each OI
was drawn. To filter out short-term fluctuations and
random variation within monthly trends, we used the
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The moving average smoothing technique achieves this
by replacing each element of the time series by n neigh-
bouring elements, where n is the width of the smoothing
window. We used a centred moving average including 3
observations before and 2 observations after the current
observation inclusive, and then generated smoothed 144
monthly prevalence series per OI.
Annualized prevalence estimates were computed for
each OI and X2 test for linear trend used to test for the
significance of the trends. To measure the rate of change
in monthly prevalence (b-coefficient) for each OI, we used
mixed effects linear regression and modelled between
monthly variability as a random effect. To test for the sig-
nificance of the difference between trends, we used krus-
kal wallis test [33]. A scatter plot and histogram of the
residuals were used to assess for assumption underlying
linear regression (i.e. linearity, normal distribution and
homogeneity of the variance). Monthly prevalence scatter
plots that were non-linear (curvilinear) were first log-
transformed before modelling the monthly rate of change
in mixed effects linear regression.
Ethical considerations
The study obtained ethical approval from Makerere Uni-
versity School of Public Health Higher Degrees Research
and Ethics committee and the Uganda National CouncilTable 1 Baseline characteristics of the cohort at the start of t
Variable Total cohort n(%) Tororo HIV cl
Sex (n = 5,972)
Female 4,301(73) 1,071 (71)
Male 1,671 (27) 433 (29)
Median age(IQR) (n = 5964) 32 (26,39) 33 (28,40)
Occupation (n = 5031)
paid employee 627(12) 120(8)
self employed 1125(22) 271(18)
peasant/unemployed 2808(56) 932(62)
others 471(9) 196(13)




Tertiary or above 220(4) 22(1)
Marital status (n = 5029)




Others 578(11) 191(13)for Science and Technology. Informed consent from
study participants was not required as this was routinely
collected operational data and the above ethical commit-
tees waived the need for consent. However, written con-
sent was obtained from TASO for conducting study and
publication of findings with any accompanying images.
Results
Baseline characteristics
A total of 204,871 monthly medical reports from a co-
hort of 5972 HIV positive patients were retrieved and
analysed. 73% (4301) were female with a median age of
32 years (inter-quartile range 26–39). More than half of
the study participants were rural poor peasants (56%)
with majority having only primary level education (50%)
and 30% were widowed (Table 1) . By 2004, only 9% of
these had access to HAART but by 2013, all (100%) who
were still in care were on HAART. The overall median
age at ART initiation was 44 years (inter-quartile range
37–50) but was significantly lower for women at 43 (inter-
quartile range 37–49) than that of men at 45 (inter-quar-
tile range 40–52) (p = 0.001). The median CD4 cell count
at the start of HAART was 128 cells (inter-quartile range
55–190) and the most commonly used HAART regimes
were zidovudine plus lamivudine and nevirapive (ZDV+
3TC+ NVP) (44%), followed by stavudine, lamivudine and
nevirapine (d4T + 3TC +NVP) (40%), and other regimenhe study, total and clinic-specific
inic n(%) Mulago HIV clinic n(%) Mbarara HIV clinc n(%)
1,368 (76) 1,862 (70)















Figure 1 Monthly prevalence trend for oral candida (orange line),
Mycobacterium tuberculosis (redline), genital ulcer (black line),
herpes zoster (green line) and cryptococcal meningitis (blue line)
expressed as a proportion of HIV-positive persons diagnosed with a
particular OI out of the total number who turned up for care per
month for the period January 2002 to December 2013.
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(TDF) and Lopinavir/ritonavir, etc. were rarely used (20%)
(Table 2).
Pre-ART (2002–2003) retention was 79% (4725/5972)
after 24 months of follow up. Post HAART (2004–2013)
mean annual retention was 90% (2237/2473) with an
average of 10% (236/2473) loss to follow up per year. In
sensitivity analysis, the female gender of those who
remained in care did not differ significantly from those
who attended but did not return (X2 = 0.475, P = 0.491).
The median age only differed by 1 year (X2 = 19, P <
0.001), with those who remained in care having median
age of 32 yrs (inter-quartile rage 27–39) while those who
were lost to follow up had a median age of 31 (inter-
quartile rage 26–38). So we assumed cases that remained
in care were a representative sample of all the cases and
that missing clinic visits happened randomly.
Prevalence and trends of OIs
Overall monthly trends for each OI are shown in Figure 1.
Best-fit regression lines, R2 and p-values for each OI are
shown in Figure 2. Baseline characteristics at the com-
mencement of HAART are shown in Table 2. Numbers of
study participants accessing HAART over time are shown
in Table 3. Average annual prevalence by each OI and
statistical tests for trend are shown in Table 4. Average
monthly changes in OI prevalence over time after con-
trolling for age, sex and clinic as fixed effects and
monthly clustering as a random effect are shown in
Table 5. Figures 2, 3 and 4 show monthly prevalence
trend comparisons by sex, age and HIV clinic. Genital
ulcer and Herpes zoster monthly prevalence decreased
linearly with time, whereas TB and oral candida monthly





Total on ART n(%) Tororo H
In care
2002 5972 - - -
2003 4725 1247(−21) - -
2004 3896 829(−18) 371(9) 1181
2005 3551 345(−9) 837(23) 1261
2006 2980 571(−16) 934(32) 972
2007 2401 579(−19) 1051(43) 863
2008 2087 314(−13) 1135(54) 823
2009 2127 42(+2) 1281(60) 887
2010 2190 63(+3) 1693(77) 888
2011 2002 188(−9) 1741(87) 689
2012 1724 278(−14) 1724(100) 578
2013 1772 48(+3) 1772(100) 592
LFU = Lost to follow up.time, decreasing rapidly between 0-48months and there-
after levelled off in the following months.
Mycobacterium tuberculosis
TB monthly prevalence was curvilinear with a steep de-
clining trend between 2003 and 2005 and thereafter
dismal change in prevalence was observed (Figure 1).
The mean annual prevalence dropped from 76.9/1000
persons at risk in 2002 to 6.6/1000 persons at risk in
2012 but slighly increased to 11.0/1000 persons at risk
in 2013 (p < 0.0001, X2trend) (Table 4). The largest reduc-
tion occurred in 2005 (52%), but thereafter there was
dismal change in prevalence (Table 4). TB monthly
prevalence trends were not different by sex (X2 = 0.19,
p = 0.66, kruskal wallis) (Figure 3) but differed significantlyand those on ART each year
IV clinic n(%) Mulago HIV clinic n(%) Mbarara HIV clinic n(%)
On ART In care On ART In care On ART
- - - - -
- - - - -
- 1185 252(21) 1530 119(8)
61(5) 1157 343(30) 1133 433(38)
71(7) 931 392(42) 1077 471(44)
84(10) 686 438(64) 852 529(62)
101(12) 581 466(80) 683 568(83)
176(20) 579 497(86) 661 608(92)
557(63) 570 514(90) 632 622(98)
577(84) 558 524(94) 655 640(98)
578(100) 515 515(100) 631 631(100)
592(100) 533 533(100) 647 647(100)
Figure 2 Scatter plot and fitted regression line for monthly prevalence over time (in months) for each OI expressed as a proportion of HIV-positive
persons diagnosed with a particular OI out of the total number who turned up for care per month for the period January 2002 to December 2013.
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HIV clinic (X2 = 94.7,p = 0.0001, kruskal wallis) (Figure 5).
After adjusting for age, sex and clinic as fixed effects and
monthly clustering as a random effect in a mixed effects
linear regression model, average monthly prevalence de-
clined at a rate of 2% per month (p < 0.05). However therate of decline differed significantly by age, sex and clinic
(p < 0.05) (Table 5).
Oral candida
Oral candida monthly prevalence also showed a curvilin-
ear trend with a steep declining trend between 2003 and
Table 3 Background characteristics of the study participants at commencement of HAART, total and sex segregated
Characteristic Total (N = 1741) Female (N = 1413) Male (N = 328) p-value*
Age in years, median (IQR) 44(37,50) 43(37,49) 45(40,52) 0.001
WHO stage III & IV, n (%) 1113(63.9) 929(65.7) 184(56.1) 0.121
CD4 cells/μl, median (IQR) (2005–6) 128(55,190) 144(65,191) 49(39,92) 0.074
ART regime (2005–2013), n (%)
d4T + 3TC+ NVP 693(40) 638(45) 136(41) 0.233
ZDV +3TC + NPV 774(44) 562(40) 131(40)
other 274(16) 213(15) 61(19)
Key: *Chi2-Test; IQR = Interquartile range; ART = Antiretroviral therapy; d4T = Stavudine; 3TC = Lamivudine, NVP = Nevirapine; ZDV = Zidovudine, WHO =World
Health Organisation.
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served (Figure 1). The mean annual prevalence dropped
from 173/1000 persons at risk in 2002 to 6.7/1000 persons
at risk in 2013 (p < 0.0001, X2trend) (Table 4). The largest re-
duction in mean annual prevalence occurred in 2005 (61%)
(Table 4). The monthly Oral candida prevalence trends
were not significantly different by sex (X2 = 0.6, p = 0.44,
kruskal wallis) (Figure 2) and age (X2 = 1.7,p = 0.42, kruskal
wallis) (Figure 3) but differed significantly by clinic
(Figure 4) with Mbarara HIV clinic (south western region)
showing the highest prevalence trend, followed by Mulago
HIV clinic (central region) and then Tororo HIV clinic
(eastern region) (X2 = 63.2, p = 0.0001, kruskal wallis). After
adjusting for age, sex and clinic as fixed effects and monthly
clustering as a random effect in a mixed effects linear
regression model, average monthly prevalence declined at a
rate of 3% per month (p < 0.001) (Table 5). However the
rate of decline did not differ significantly by age or sex (p >
0.05) but differed significantly by clinic (p < 0.05) (Table 5)
Herpes zoster
Herpes zoster monthly prevalence showed a consistent
declining trend (Figure 1). The mean annual prevalenceTable 4 Mean annual OI prevalence (per 1000) in a cohort of
Uganda
Before HAART Early HAART
OI 2002 2003 2004 2005 2006
Cryptococcal meningitis 5.5 5.4 2.5 3.3 2.7
% change - 0 −54 +32 −18
Mycobacterium tuberculosis 76.9 45.5 29.3 16.2 9.6
% change - −41 −36 −45 −41
Herpes zoster 13.4 13.9 11.5 9.1 7.6
% change - +4 −14 −25 11
Oral candida 172.7 106.4 83.1 32.3 26.5
% change - −38.7 −20 −62 −16
Genital ulcer(HSV-2) 15.1 18.2 17.6 12.3 9.3
% change - +21 3.3 −33 −17
Key: HAART = Highly active antiretroviral therapy; % = percent; HSV-2 = Herpes simpreduced from 13.4/1000 persons at risk in 2002 to 3.3/
1000 persons at risk in 2013 (p = 0.0002, X2trend) (Table 4).
Largest reduction in mean annual prevalence was ob-
served in 2008 (53.4%) (Table 4). However, Herpes
zoster monthly trends were not significantly different
by sex (X2 = 0.08, p = 0.77, kruskal wallis) and clinic
(X2 = 2.4, p = 0.29, kruskal wallis) but differed signifi-
cantly by age (X2 = 7.2,p = 0.027, kruskal wallis). After
adjusting for age, sex and clinic as fixed effects and
monthly clustering as a random effect in a mixed effects
linear regression model, monthly prevalence declined
significantly at an average rate of 0.087 per month (p <
0.001). However this rate of decline did not differ signifi-
cantly by age, sex and clinic (p > 0.05) (Table 5).
Genital ulcer
The prevalence of genital ulcer was relatively lower
when comapred to Oral candida and TB. Monthly
prevalence slightly but significantly reduced over the ob-
servation period (Figure 1). The mean annual prevalence
dropped from 15.1/1000 persons at risk in 2002 to 8.9/
1000 persons at risk in 2013 (p = 0.0029, X2trend) (Table 4).
Its monthly prevalence series were significantly differentHIV positive individuals before and after HAART in
Late HAART
2007 2008 2009 2010 2011 2012 2013 X2trend (p-value)
2.7 1.6 1.2 4.0 1.3 1.3 0.23 1.79 (0.1807)
0 −41 −25 +233 −67 0 −82
13.2 9.0 10.9 9.1 7.4 6.6 11.0 157.38 (<0.0001)
+37 −32 +21 −16 −19 −11 +67
10.0 5.1 5.0 3.8 3.7 3.7 3.3 13.67 (0.0002)
+37 −54 2 −24 −20 0 −11
20.0 17.0 12.0 12.6 15.4 8.7 6.7 458.20 (<0.0001)
−26 −10 −33 +8 −23 −37 −20
12.0 11.2 8.1 9.2 7.2 7.7 8.9 8.8 (0.0029)
+20 −8 27 +25 −20 −12.5 +43
lex virus type2.
Table 5 Mixed effects linear regression analysis of monthly rate of change in the prevalence of each OI (per 1000) adjusted for fixed effects (age, sex and
clinic) and random effects (monthly clustering)
Cryptococcal meningitis1 Mycobacterium tuberculosis2 Herpes zoster Oral candida3 Genital ulcer
β(95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
[p-value] [p-value] [p-value] [p-value] [p-value]
Predictor variable
(Fixed effect)
Time* −0.003 (−0.004 to −0.002) [<0.001] −0.023 (−0.023 to −0.022) [<0.001] −0.087 (−0.09 to −0.08) [<0.001] - 0.0296 − 0.0298 to −0.0293) [<0.001] −0.078 (−0.08 to −0.07) [<0.001]
Sex
Female 1 1 1 1 1
Male 0 .0058 (−0.042 to 0.054) [0.813] 0.035 (0.010 to 0.059) [0.004] 0.15 (−0.55 to 0.24) [0.449] −0.008 (−0.021 to 0.004) [0.197] 0.083 (−0.45 to 0.61) [0.758]
Age
<30 yrs 1 1 1 1 1
30–39 −0.022 (−0.073 to 0.028) [0.387] −0.021 (−0.046 to 0.004) [0.096] 0.11 (−0.29 to 0.51) [0.588] 0.0002 (−0.012 to 0.013) [0.980] 0.004 (−0.48 to 0.47) [0.986]
40+ −0.041 (−0.10 to 0.020) [0.187] - 0.035 (−0.066 to −0.003) [0.032] −0.05 (−0.54 to 0.44) [0.841] 0.007 (−0.007 to 0.021) [0.341] 0.49 (−0.11 to 1.09) [0.110]
HIV clinic
Tororo 1 1 1 1 1
Mulago −0.022 (−0.073 to 0.028) [0.387] −0.089 (−0.12 to −0.062) [<0.001] 0.22 (−0.26 to 0.70) [0.373] −0.02 (−0.042 to −0.002) [0.032] 0.25 (−0.84 to 0.34) [0.414]
Mbarara −0.091 (−0.15 to −0.035) [0.001] −0.12 (−0.15 to −0.088) [<0.001] 0.10 (−0.35to .55) [0.666] −0.020 (−0.038 to −0.002) [0.028] 0.45 (−1.04to 0.13) [0.130]
Constant 0.77 4.39 14.7 5.3 18.6




δ2μ 0.006 0.001 0.94 0.002 2.8
(95% CI) (0.0023 to 0.017) (0.0005 to 0.004 (0.39 to2.26) (0.001 to 0.005) (1.2 to 6.5)
[SE] [0.003] [0.0006] [0.42] [0.001] [1.20]
δ2ε 0.041 0.11 0.33 0.060 17.2
(95% CI) (0.036 to 0.048) (0.10 to 0.11) (7.6 to 9.1) (0.058 to 0.062) (16.0 to 18.5)
[SE] [0.003] [0.0026] [0.368] [0.001] [0.62]
Key: *Time =144 months, β = beta coefficient, SE = standard error, CI = confidence interval, δ2ε = Residual variance.
δ2μ = random effect monthly variance.
1Natural log monthly prevalence (per 1000) of Cryptococcal meningitis.
2Natural log monthly prevalence (per 1000) of Mycobacterium tuberculosis.













Figure 3 Monthly prevalence trend for each OI by sex: female (blue line), male (maroon line); expressed as a proportion of HIV-positive persons
diagnosed with a particular OI out of the total number who turned up for care per month for the period January 2002 to December 2013.
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than men (X2 = 14.8, p = 0.0001, kruskal wallis) (Figure 3).
The monthly series were also significantly different by
age with HIV positive clients aged between 30-39 yrs
having a relatively higher prevalence compared to those
aged below 30 years and those aged 40 years and above
(X2 = 10.6, p = 0.005, kruskal wallis) (Figure 4). The
monthly series also differed significantly by HIV clinic
with Mulago HIV clinic (central region) showing thehighest prevalence trend, followed by Mbarara HIV
clinic (south western region) and then lastly Tororo HIV
clinic (eastern region) (X2 = 45.3, p = 0.0001) (Figure 5).
After adjusting for age, sex and clinic as fixed effects
and monthly clustering as a random effect, monthly
prevalence declined significantly at an average rate of
0.078 per month. However the rate of decline did not
differ significantly by age or sex or clinic (p > 0.05)
(Table 5).
Figure 4 Monthly prevalence trend for each OI by age: <30 yrs (blackline), 30-39 yrs (greenline) & 40 yrs and above (redline); expressed as a
proportion of HIV-positive persons diagnosed with a particular OI out of the total number who turned up for care per month for the period
January 2002 to December 2013.
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Figure 5 Monthly prevalence trend for each OI by HIV clinic: Mulago HIV clinic (orange line), Tororo HIV clinic (blackline), and Mbarara HIV clinic
(blue line); expressed as a proportion of HIV-positive persons diagnosed with a particular OI out of the total number who turned up for care per
month for the period January 2002 to December 2013.
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Crypotococcal meningitis prevalence was relatively the
lowest in this cohort and showed a non-significant trend
(Figure 1). The prevalence decreased between 2003 and
2004 but showed intermittent decreasing and increasing
trends between 2005 and 2013 with a peak increase ob-
served in 2010. The mean annual prevalence reduced
from 5.5/1000 persons at risk in 2002 to 1.2/1000 per-
sons at risk in 2009, then increased to 4.0/1000 persons
at risk in 2010 and thereafter declined to 0.23/1000 per-
sons at risk in 2013 (p = 0.181, X2trend). The monthly
series were not significantly different by sex (X2 = 3.48,
p = 0.062, kruskal wallis) and age (X2 = 3.7, p = 0.15,
kruskal wallis) but were significantly different by HIV
clinic (X2 = 15.2, p = 0.0005, Kruskal Wallis). After
adjusting for age, sex and clinic as fixed effects and
monthly clustering as a random effect, monthly preva-
lence declined significantly at an average rate of 0.3%
per month. However the rate of decline did not differ
significantly by age or sex or clinic (p > 0.05) (Table 5)
Discussion
On average globally, TB prevalence among HIV+ indi-
viduals slightly reduced from around 25% in 2007 to
21% in 2010 [34]. In the current study, we have observed
a significant declining trend in mean annual prevalence
of Mycobacterium tuberculosis. This is consistent with
other previous studies, for example, a study in the USA
that evaluated annual trends for 13 most common
AIDS-defining opportunistic infections by examining
medical records in more than 90 hospitals and clinics in
9 US cities before HAART (1991–96) and showed de-
creasing trends in tuberculosis [11]. Another study in
Italy that examined temporal trends in the incidence of
opportunistic infections (OIs) associated with AIDS in
the period 1989–1997 showed significant decreasing
trends in both pulmonary and extra-pulmonary tubercu-
losis [20]. However, differs from a cohort study in west
London who investigated the incidence of 12 most fre-
quent AIDS-defining illnesses in the pre-HAART and
post-HAART time periods and found no significant reduc-
tion in the incidence of TB and other OIs but significant
decrease in the incidence of PCP, Kaposis sarcoma and
cryptosporidiosis [35].
Few studies though have examined the trends in preva-
lence of TB among HIV+ individuals in low income set-
tings. One study in South Africa examined the trends in
incidence rates of TB before HAART (1991–2000) re-
ported a non-significant increasing trend of TB incidence
(P = 0.17, X2trend) [22]. Another study in Malawi that exam-
ined trends in TB associated with HIV-infection between
1988 to 2001 showed incidence of active TB first increased
up to 1990 and thereafter started to decline [36]. Uganda
is among the 22 high-burden TB countries in the world[37] and previous studies in Uganda show that over 80%
of the HIV-related morbidity and 30% of the HIV related
death were due to TB [4,38]. TB co-infection with HIV
has been associated with poor HAART prognostic out-
comes [39]. A prospective cohort study that assessed the
effect of HAART on TB incidence in Eastern Uganda
showed TB reduced from 7.2% at baseline to 5.5% after
1.4 yrs of follow up [38]. Our findings are consistent with
these previous findings and provide additional evidence of
a significant HAART effect on TB prevalence in resource
poor settings. However, the slight increase observed in
2013 implies that TB may never be completely eliminated
since it is endemic in these settings and was even there be-
fore the advent of the HIV epidemic in Uganda.
Herpes zoster showed a significant declining trend
though the effect of HAART seems to be relatively less
compared to other OIs. Our findings are consistent with
findings from a study in the USA that evaluated the ef-
fect of HAART on incidence trends of Herpes zoster
from 1987 to 2011 and reported a significant reducing
trend in annual incidence of Herpes zoster [40]. How-
ever our findings deviates from another study that
followed HIV- infected patients from 1985 to 2003 in
France found no significant difference in the incidence
rate for Herpes zoster over time [41]. Another study in
the USA reported an increasing trend in the prevalence
of clinical Herpes zoster in the period from 1945 to
2008 [42]. Our findings provide additional evidence that
increasing coverage of HAART is having a significant ef-
fect on Herpes zoster even in resource poor settings.
However this effect on prevalence could also be attrib-
uted to increasing availability of other potent antiviral
drugs like acyclovir.
Oral candida showed very sharp decline of 61% in
2005 probably because of the introduction of HAART in
2005 and increased availability of more potent systemic
antifungal drugs like fluconazole. This is consistent with
recent study findings in Spain which examined trends of
candidiasis among HIV+ children (<15 years) for the
period 1997–2008 and found significant decline in can-
didaisis diagnoses in this time period attributed to the
effect of HAART . However, another study in the USA
that reviewed the trends in the epidemiology of oppor-
tunistic fungal infections associated with HIV/AIDS
showed a significant increasing trend in the incidence
of fungal infections (Aspergillus sp) attributed to in-
creasing resistance to anti-fungal treatment and recom-
mended documentation of epidemiological trends to
gain more insights into the effectiveness of treatment
strategies [19]. Though a significant declining trend
was observed, the OI has not been completely elimi-
nated probably because it is highly endemic in Uganda
or there could also be drug resistance which requires
further investigations.
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type2 have previously been shown to be common among
HIV positive patients [43-45]. A study in France found
about 18% of the HIV infected adults were co-infected
with herpes simplex virus type2 [46]. Herpes simplex
virus-2 infection can be latent in the normal human body
but become reactivated when the immune system is se-
verely compromised [47]. In Uganda, a rural population
study found the rate ratio for HSV-2 incidence was 3.69 in
HIV-positive cases with genital ulcers compared to HIV-
negative persons after adjusting for age and sex [43]. The
study also found the prevalence of HSV-2 was much
higher in women (71.5%) than in men (36.6%). Our study
shows prevalence of genital ulcers declined slightly over
time and the trends differed significantly by sex. A study
in India reported an increasing prevalence trend of genital
herpes between 2000 to 2004 but prevalence was reported
higher in women compared to men [48]. Similar findings
were also reported in another study in India [49]. Our
findings provides additional evidence that increased avail-
ability of HAART and effective treatment particularly
acyclovir could be responsible for the observed decline in
the prevalence of genital ulcers in Uganda.
In the current study Cryptococcal meningitis showed a
non-significant declining trend with a 50% reduction in
2004 probably due to the introduction of fluconazole
around this time and highly active antiretroviral therapy
in 2005 [50]. The overall declining trend is consistent
with other previous studies in developed countries which
also reported declining trends in the era of HAART. A
study in Brazil [21] examined temporal trends in incidence
of opportunistic infections (OI) among HIV-infected
adults (>12 years old) at a national level for the period in
1980–1999. The study showed a declining trend for all OI
including Cryptococcal meningitis among adult AIDS
cases particularly after the introduction of HAART in
1996. In the USA, a population based surveillance for
cryptococcosis conducted between 1992 and 2000 re-
ported a declining trend in the incidence of cryptococcosis
among HIV+ individuals attributed to widespread use of
effective antiretroviral drugs [51]. Another study [19] that
reviewed trends in epidemiology of opportunistic fungal
infections showed that increasing use of effective antifun-
gal prescriptions has reduced the frequency of invasive
mycoses including cryptococcosis among HIV+ individ-
uals in the US. Our study adduces more evidence that
cryptococcosis is reducing among HIV+ individuals over
time with increasing access to HAART and fluconazole in
Uganda. However the slight increase in 2010 could be at-
tributed to improvement in diagnosis following the intro-
duction of the lateral flow cryptococcal Antigen (CrAg)
rapid test strips [50,52]
The study also shows that complete elimination of op-
portunistic infections may not be possible partly becausethey are endemic and also as a consequence of gaps in
timely access to treatment, poor adherence to HAART,
inadequate staff and laboratory equipment, poverty and
high patient attrition [53]. We also observed a mean an-
nual attrition rate of 10% in the era of HAART whose
cause we can only speculate. Previous studies have
shown that despite the best efforts by care providers and
donors to provide free lifelong ARVs, HIV patients
would still drop out of programme care or withdraw
from treatment for various reasons [54-57]. Sydney
Rosen and colleagues in their systematic review on
prevalence of loss to follow up among patients on ART,
reported an average 40% prevalence of loss to follow up
[56]. Some studies have also shown retention at 24 month
in most ART programmes in Sub-Saharan Africa to be be-
tween 60-80% [56,58]. In Uganda, ART attrition rates after
12 months have been reported to reach up to 30% [53,59]
while generally, among ART patients who are subject to
attrition, i.e. who are lost to follow-up (LTFU), it is esti-
mated that 30-60% are dead [53,59,60].
Lastly, missed clinic visits are inevitable over a lifelong
HIV/AIDS care programme. However, our understanding
of why people drop out of care and how to address this
problem remains limited [61]. Norma Ware and col-
leagues conducted a large qualitative study among patients
in HIV treatment programs in sub-Saharan Africa to in-
vestigate reasons for missed clinic visits and reported both
intentional and unintentional reasons including cost of
transport to the clinic, stigma and dissatisfaction with
care, competing demands (both economic and social),
finding an alternative source of care and discouragement
due to perceived harsh treatment by care providers [57].
However, these factors are likely to vary from one geo-
graphical setting to another. Hence, it is crucial to cor-
rectly identify these factors so as to improve ART
program retention and success in resource poor settings.
Limitations
This study had a number of limitations. First, data ana-
lysed was limited to what was available in the TASO
electronic data base and so certain variables whose data
was not captured could not be analysed. Being a retro-
spective cohort, there was no information available on
the clients who never returned for care. So we did not
have information on the connection to care or survival
status of clients who were lost to follow up. However we
assumed that these simply relocated to another clinic for
care or died as had been reported in other previous
studies [54,55,59,62,63]. The TASO clients whose med-
ical records were analysed may have not been represen-
tative of all HIV+ individuals in Uganda which means
generalisability could be limited but still this does not
compromise the evidence we have adduced since most if
not all beneficiaries of public health care programmes in
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been a possibility that some OIs went away undiagnosed
or were not recorded during clinic visits as was reported
in a previous study conducted in Uganda [64]. Though
we believe this was minimized by selected OIs which
were easy to diagnose and of great interest in the coun-
try given that the study by Kiragga et al. [64] reported
that the level of under reporting was far less for TB and
Cryptococal meningitis compared to other less import-
ant OIs. From sensitivity analysis, we established that
cases who remained in care were not significantly differ-
ent from those that were lost to follow up and so we
conservatively assumed that cases who remained in care
were a representative sample of all the cases in the ori-
ginal cohort and that missing clinic visits happened ran-
domly. Even with these limitations, there is sufficient
evidence that increasing HAART availability in resource
poor settings is having a meaningful impact on preva-
lence of opportunistic infections.
Conclusions and recommendations
Overall, the data provides emperical evidence that the
disease burden due to OIs has significantly reduced in
the 12 years of follow up. The decrease in trends of indi-
vidual OIs could be attribute to the increased access to
HAART and other preventive prescriptions such as
cotrimoxazole prophylaxis and effective therapeutic
drugs over time. The study further shows that some op-
portunistic infections were still common though at re-
duced prevalence in spite of availability of effective
treatment including HAART. This is probably because
they are endemic or this could be a sign of resistance/
treatment failure that needs to be further investigated.
The differences in trends between OIs and geographical
areas were likely to be due to differences in the level of
exposure to infectious agents, social-economic status,
drug resistance, immunity, nutrition, etc. Future research
should explore the association of these factors with
trends of individual OIs and knowledge of these factors
could help in the design of taregeted interventions. The
effect attributable to HAART alone or Cotrimoxazole
prophylaxis and other therapeutic drugs was not estab-
lished as this would require a comparison cohort which
is exclusively on HAART alone which was not available.
We recommend that future studies should examine this
aspect. We also recommend that information on those
lost to programme care should be routinely collected in
order to have insight on the causes for drop out which
will ultemately help to improve ART programmes and
inform policy decisions on improvement of treatment
outcomes in resource poor settings.
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